EGR1 promoted anticancer effects of Scutellarin via regulating LINC00857/miR‐150‐5p/c‐Myc in osteosarcoma

Abstract

Scutellarin, an active flavone extracted from Erigeron breviscapus, is known to exhibit antitumour activity in many cancers. However, the effects of Scutellarin on osteosarcoma remain unclear. In this study, we found that Scutellarin suppressed osteosarcoma cell growth, induced cell apoptosis and inhibited tumorigenesis. Mechanistically, our data revealed that EGR1 was significantly increased under Scutellarin treatment. Increased EGR1 enhanced tumour‐suppressive effects of Scutellarin on osteosarcoma cells via transcriptionally downregulating LINC00857 expression. Additionally, we found that LINC00857 acted as a competitive endogenous RNA of miR‐150‐5p and inhibited the activity of miR‐150‐5p, which resulted in c‐Myc increase. Scutellarin could suppress c‐Myc protein levels through decreasing LINC00857 expression in osteosarcoma. Thus, these findings demonstrate that EGR1/ LINC00857/miR‐150‐5p/c‐Myc axis plays a key role in promoting anticancer effects of Scutellarin and Scutellarin might have potential clinical implication in osteosarcoma clinical treatment.

Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients

“…Early growth response protein-1 (EGR1) encodes a zinc finger protein of the EGR family, which is involved in transcriptional regulation ( Wang et al, 2021c ). Based on the findings of Han et al, LINC00857/miR-150–5p/c-Myc modulated anticancer effects of Scutellarin via EGR1 ( Han et al, 2021 ).…”